Growth Metrics

Moderna (MRNA) Cash from Investing Activities (2018 - 2025)

Moderna (MRNA) has disclosed Cash from Investing Activities for 8 consecutive years, with -$48.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 91.09% to -$48.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, changed 0.15% year-over-year, with the annual reading at $1.9 billion for FY2025, 0.15% changed from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$48.0 million at Moderna, down from $700.0 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $2.0 billion in Q1 2023, with the low at -$3.9 billion in Q1 2022.
  • Average Cash from Investing Activities over 5 years is -$279.9 million, with a median of $35.0 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities tumbled 29930.77% in 2021, then soared 518.64% in 2025.
  • Over 5 years, Cash from Investing Activities stood at -$1.1 billion in 2021, then increased by 7.91% to -$1.0 billion in 2022, then skyrocketed by 48.66% to -$538.0 million in 2023, then fell by 0.19% to -$539.0 million in 2024, then surged by 91.09% to -$48.0 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$48.0 million, $700.0 million, and $564.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.